PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
391 episodes - English - Latest episode: 26 days ago - ★★★★★ - 3 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Geoffrey Barnes, MD, MSc - Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention
April 22, 2022 23:00 - 1 hour VideoGo online to PeerView.com/TFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in the management of venous thromboembolism (VTE) discuss the importance of a timely diagnosis, appropriate treatment selection, and extended anticoagulation therapy for secondary prevention. Upon completion of this activity, participants should be better able to: Apply appropriate evidence-based clinical decision tools in an inter...
Gregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?
April 15, 2022 23:00 - 1 hour VideoGo online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated fo...
John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs
April 04, 2022 23:00 - 32 minutes VideoGo online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine curren...
Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
April 04, 2022 23:00 - 1 hour VideoGo online to PeerView.com/CRA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. While remarkable data have emerged from several trials assessing ICIs and rational combinations in neoadjuvant and/or adjuvant settings, many questions remain. What are the pros/...
Purvi S. Parikh, MD, FACP, FACAAI / Cedric ""Jamie"" Rutland, MD - Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma
April 01, 2022 23:00 - 57 minutes VideoGo online to PeerView.com/FTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma detail the pathophysiology of severe asthma, with a discussion of the underlying mechanisms behind both type 2 and non–type 2 asthma, and novel and emerging therapies for its treatment. Upon completion of this CE activity, participants will be able to: Discuss unmet treatment needs for patients with severe, uncontrolled asthm...
Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors
March 31, 2022 23:00 - 28 minutes VideoGo online to PeerView.com/BNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the expanding role of macrocyclic TKIs in the treatment of fusion-positive NSCLC and other solid tumors. Upon completion of this activity, participants should be better able to: Discuss the structure and mechanisms of action of macrocyclic tyrosine kinase inhibitors (TKIs) and their role in the treatment of fusi...
Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do
March 16, 2022 23:00 - 59 minutes VideoGo online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Convers...
Paneez Khoury - Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes
February 28, 2022 23:00 - 33 minutes VideoGo online to PeerView.com/DMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hypereosinophilic syndrome discusses the burden, symptoms, and differential diagnosis of the disease, as well as the latest data on treatment. Upon completion of this CE activity, participants will be able to: Describe the burden of hypereosinophilic syndrome (HES) on patients, including the consequences of underdiagnosed and unde...
Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
February 15, 2022 23:00 - 1 hour VideoGo online to PeerView.com/GWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The transformation of patient care in diffuse large b-cell lymphoma (DLBCL), driven by advances with antibodies and cellular therapy, continues—what will this mean for your practice? Find out in PeerView’s “Clinical Consults” video activity where a panel of DLBCL will focus on the applications of these dual innovations in the management of DLBCL. Using a series...
Lorinda Chung, MD, MS - Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities
February 01, 2022 23:00 - 59 minutes VideoGo online to PeerView.com/MVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in SSc-ILD discuss how to accurately interpret HRCT patterns, the latest diagnosis and management guidelines, including the importance of identifying and treating comorbidities, and the efficacy and safety of novel and emerging therapies. Upon completion of this CE activity, participants will be able to: Recognize signs, symptoms, and ...
Biree Andemariam, MD - The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities
February 01, 2022 23:00 - 1 hour VideoGo online to PeerView.com/CMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in sickle cell disease discuss current and future disease management strategies, including recent safety, efficacy, and tolerability data for currently approved and emerging therapies. Upon completion of this CE activity, participants will be able to: Discuss the disease burden, etiopathogenesis, complications, and unmet needs associat...
Neal K. Lakdawala, MD - Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment
January 26, 2022 23:00 - 1 hour VideoGo online to PeerView.com/TCX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is a clinically complex disease that is often undiagnosed or misdiagnosed. The mechanisms behind its pathophysiology are not yet fully understood, but HCM has multiple underlying drivers, including cardiac muscle hypercontractility. It is the most common genetic heart disease and follows an autosomal dominant pattern with a poo...
Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care
January 26, 2022 23:00 - 1 hour VideoGo online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also provi...
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease
January 24, 2022 23:00 - 1 hour VideoGo online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions rem...
John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management
January 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of...
Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers
January 11, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuv...
"Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers"
January 11, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuv...
Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care
December 30, 2021 23:00 - 1 hour VideoGo online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profilin...
Flavia Castelino, MD / Sonye K. Danoff, MD, PhD - The Evolving Treatment Landscape of SSc-ILD: Strategies to Improve Recognition and Management
December 28, 2021 23:00 - 1 hour VideoGo online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mai...
David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC
December 20, 2021 23:00 - 1 hour VideoGo online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Con...
Stephen V. Liu, MD / Bhavesh Shah, RPh, BCOP - Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan
December 18, 2021 23:00 - 1 hour VideoGo online to PeerView.com/TMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and managed care provide a foundational overview of the mechanism of action of cancer immunotherapies and why this class of agents is different from other oncologic therapies. The panel also explores how immunotherapies have revolutionized the management of cancer over the last few years, particularly the ways in which SCLC...
Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?
December 16, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/AZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView Clinical Consults activity features cardio-oncologist Javid Moslehi, MD, and medical oncologist Douglas B. Johnson, MD, MSCI, who explain why greater awareness is needed among cardiology professionals about the cardiac toxicities associated with cancer immunotherapies, known as immune-related adverse events (irAEs), and their clinical manifestatio...
David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer
December 14, 2021 23:00 - 57 minutes VideoGo online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a grow...
Gwen A. Huitt, MD, MS - Addressing Challenges in the Treatment of Nontuberculous Mycobacterial Lung Disease: Managing Adverse Effects to Keep Patients on Therapy
December 09, 2021 23:00 - 33 minutes VideoGo online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to p...
Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings
December 08, 2021 23:00 - 58 minutes VideoGo online to PeerView.com/KPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid progress in the treatment of EGFR-mutated non–small cell lung cancer (NSCLC) has practice-changing implications for pathologists, oncologists, and the broader multidisciplinary lung cancer care team. In addition to multiple targeted therapy options available for patients with metastatic NSCLC with more commonly occurring EGFR mutations, new agents have re...
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM
December 02, 2021 23:00 - 53 minutes VideoGo online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indicati...
Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
November 29, 2021 23:00 - 1 hour VideoGo online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what’s showing the most promise next. Clinical and research updates are combined with case-based demonstrations ...
Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team
November 09, 2021 23:00 - 35 minutes VideoGo online to PeerView.com/AEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGC...
"Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies"
October 25, 2021 23:00 - 27 minutes VideoGo online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic wo...
Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies
October 25, 2021 23:00 - 27 minutes VideoGo online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic wo...
Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
October 19, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in gu...
Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
October 19, 2021 23:00 - 1 hour VideoGo online to PeerView.com/ZZW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in myelofibrosis discuss risk stratification, individualized care, and treatment strategies, including the use of JAK inhibitors and JAK inhibitor–based combinations. Upon completion of this accredited CE activity, participants should be better able to: Review modern risk stratification models, molecular features, cytogenetics, and cli...
Daniel Jacoby, MD - Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology
October 19, 2021 23:00 - 52 minutes VideoGo online to PeerView.com/BQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live satellite symposium held at HFSA 2021, expert faculty review the evidence for current and emerging treatment strategies for hypertrophic cardiomyopathy (HCM) using patient cases to illustrate the ways in which clinicians can adapt current practices and utilize shared decision-making to offer appropriate treatment options...
"Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC"
October 19, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in gu...
Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies
October 14, 2021 23:00 - 1 hour VideoGo online to PeerView.com/ECV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative ...
Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care
October 13, 2021 23:00 - 1 hour VideoGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. Th...
Jared Weiss, MD - Raising the Bar for Patient Outcomes With Transcription Inhibition and Other New Options in the Treatment Arsenal for SCLC: Rationale, Mechanisms of Action, Latest Data, and Practicalities of Clinical Use in Oncology Practice
October 12, 2021 23:00 - 54 minutes VideoGo online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options a...
Ian Pavord, FMedSci - Across the Age Spectrum: Expert Insights on Emerging Uses of Targeted Therapy for the Treatment of Uncontrolled Moderate to Severe Asthma
October 12, 2021 23:00 - 34 minutes VideoGo online to PeerView.com/DWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma. Upon completion of this accredited CE activity, participants should be better able to: Explain to peers the latest developments i...
Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment
October 11, 2021 23:00 - 51 minutes VideoGo online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, an...
"Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL"
October 11, 2021 23:00 - 1 hour VideoGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to p...
Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL
October 11, 2021 23:00 - 1 hour VideoGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to p...
Sanam Loghavi, MD - Secondary AML Through the Microscope: A Pathology-Informed Guide to Modern Diagnostic and Treatment Principles
October 06, 2021 23:00 - 28 minutes VideoGo online to PeerView.com/SFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered. Upon completion of this accredited CE activity, ...
Stephen V. Liu, MD - Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical
October 06, 2021 23:00 - 1 hour VideoGo online to PeerView.com/DDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The broad implications of the expanding role of cancer immunotherapies in lung cancer necessitate multidisciplinary collaboration, especially in the locally advanced setting where appropriate patient evaluation and selection for immune checkpoint inhibitors (ICIs) along with other multimodal therapies requires input from a medical oncologist, a radiation oncolo...
Stephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment
September 29, 2021 23:00 - 1 hour VideoGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory ...
Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC
September 29, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/CBB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs ...
Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics
September 28, 2021 23:00 - 1 hour VideoGo online to PeerView.com/GXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the ...
Ruben A. Mesa, MD, FACP - A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
September 10, 2021 23:00 - 37 minutes VideoGo online to PeerView.com/CCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the molecular genetics, cytogenetics, and clinical features of myelofibrosis as well as modern prognostic scoring sys...
Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies
August 31, 2021 23:00 - 55 minutes VideoGo online to PeerView.com/ESW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies. Upon comp...
Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes
August 17, 2021 23:00 - 46 minutes VideoGo online to PeerView.com/NWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss the diagnosis of cancer-associated VTE, review the latest data and guidelines on currently available treatment options, and suggest strategies for including interprofessional collaboration in routine clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Assess the ...
Nicola Gökbuget, MD - Achieving Therapeutic Innovation in ALL: Insights on Modern Asparaginase Compounds in Pediatric, AYA, and Adult Patients
August 06, 2021 23:00 - 1 hour VideoGo online to PeerView.com/JPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity features case-based expert discussions on the use of asparaginase in the context of broader innovations in ALL care across pediatric, AYA, and adult patients. Our experts give insights on standard asparaginase compounds, monitoring and management of toxicities, hypersensitivity/silent inactivation, and sequential use of alternati...